Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes

Patients with myelodysplastic syndromes (MDS) often develop anaemia resulting in frequent transfusions and fatigue. Darbepoetin alfa is an erythropoiesis-stimulating agent (ESA) approved for treating chemotherapy-induced anaemia. This single-arm, phase 2 study examined the efficacy of darbepoetin al...

Descripción completa

Detalles Bibliográficos
Autores principales: Gabrilove, Janice, Paquette, Ronald, Lyons, Roger M, Mushtaq, Chaudhry, Sekeres, Mikkael A, Tomita, Dianne, Dreiling, Lyndah
Formato: Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2008
Materias:
Haematological Malignancy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2654479/
https://www.ncbi.nlm.nih.gov/pubmed/18540943
http://dx.doi.org/10.1111/j.1365-2141.2008.07181.x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2654479/
https://www.ncbi.nlm.nih.gov/pubmed/18540943
http://dx.doi.org/10.1111/j.1365-2141.2008.07181.x

Ejemplares similares